MUMBAI, India, Aug. 17 -- Intellectual Property India has published a patent application (202617084266 A) filed by Catavax Inc on July 09, 2026, for Cancer Vaccine Based On Mhc-Ii Epitope Selection.
Inventors include Nielsen, Morten; Holst, Peter, Johannes; and Nrgaard, Anders, Kaare.
The application for the patent was published on August 14, 2026, under issue no. 33/2026.
Abstract: The present disclosure provides a vaccine against cancers that express MHC-II. That includes hormone positive breast cancers and some prostate cancers and melanoma. It is possible, based on a genomic test of the individual, to either (1) design a personal vaccine consisting of a polytope based on epitopes from the TAA that in most cases display on MHC-II and not on MHC-I, or (2) select previously manufactured sequences based on epitopes from the TAA as constituents of the vaccine, such that the cancer after vaccination will reveal itself to the immune system and get eradicated while there are little side effects in that the vaccine will not make the immune system harm the healthy tissue.
Disclaimer: Curated by HT Syndication.
